Timber Pharmaceuticals, Inc.
TMBR · AMEX
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $2 | $2 | $2 | $2 |
| Gross Profit | -$2 | -$2 | -$2 | -$2 |
| % Margin | – | – | -2,425.9% | – |
| R&D Expenses | $2 | $2 | $2 | $2 |
| G&A Expenses | $1 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $2 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4 | $4 | $4 | $3 |
| Operating Income | -$4 | -$4 | -$4 | -$3 |
| % Margin | – | – | -4,287.5% | – |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$4 | -$4 | -$4 | -$3 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$4 | -$4 | -$4 | -$3 |
| % Margin | – | – | -4,355.5% | – |
| EPS | -1.32 | -1.36 | -1.72 | -1.52 |
| % Growth | 2.9% | 20.9% | -13.2% | – |
| EPS Diluted | -1.32 | -1.36 | -1.72 | -1.52 |
| Weighted Avg Shares Out | 3 | 3 | 2 | 2 |
| Weighted Avg Shares Out Dil | 3 | 3 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$4 | -$3 | -$3 |
| % Margin | – | – | -4,166.6% | – |